Helicobacter pylori eradication and the prevention of peptic ulcer bleeding and cardiovascular disease progression in chronic aspirin users

Table 5 Incidence of peptic ulcer bleeding and cardiovascular events by type and number of additional antithrombotic/anticoagulant medications

Medication group	PUB incidence n/N (%)	Cardiovascular events n/N (%)	Adjusted odds ratio for PUB	95%CI for PUB	P value for PUB
By type of additional medication
Aspirin + clopidogrel	42/400 (10.5)	101/400 (25.3)	1.2	0.8-1.8	0.120
Aspirin + warfarin	39/400 (9.8)	99/400 (24.7)	1.1	0.7-1.6	0.150
Aspirin + DOACs	45/400 (11.2)	104/400 (26.1)	1.3	0.9-1.9	0.200
By number of medications
Dual therapy (aspirin + 1 drug)	35/400 (8.7)	94/400 (23.5)	1.0 (reference)	-	-
Triple therapy (aspirin + 2 drugs)	61/400 (15.2)	116/400 (28.9)	1.8	1.2-2.7	0.004

Medication-type categories (aspirin + clopidogrel/warfarin/direct oral anticoagulants) are not mutually exclusive. Patients receiving triple antithrombotic therapy contributed to all relevant medication-type groups as well as to the “triple therapy” group. All percentages are calculated using the total study cohort (n = 400) as the denominator. PUB: Peptic ulcer bleeding; CI: Confidence interval; DOACs: Direct oral anticoagulants.